

FILE 'HOME' ENTERED AT 14:46:08 ON 22 FEB 2005

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
0.21	0.21

FILE 'CAPLUS' ENTERED AT 14:46:26 ON 22 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 22 Feb 2005 VOL 142 ISS 9
FILE LAST UPDATED: 21 Feb 2005 (20050221/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>
Uploading C:\STNEXP4\QUERIES\824.str

L1 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 14:47:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 179 TO ITERATE

100.0% PROCESSED 179 ITERATIONS
SEARCH TIME: 00.00.01

2 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2778 TO 4382
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

L3 18 L2

=> s 13 and py<2002
21606142 PY<2002
L4 5 L3 AND PY<2002

=> d 1-5 ibib abs hitstr

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:730698 CAPLUS
DOCUMENT NUMBER: 135:289056
TITLE: Preparation of amidino compounds useful as nitric oxide synthase inhibitors
INVENTOR(S): Webber, Ronald Keith; Awasthi, Alok K.; Bergmanis, Arij A.; Durley, Richard C.; Ganser, Scott S.; Hagen, Timothy J.; Hallinan, Ann E.; Hansen, Donald W.; Hickory, Brian S.; Moermann, Alan E.; Pitzele, Barnett S.; Promo, Michelle A.; Schartman, Richard R.; Snyder, Jeffrey S.; Trivedi, Mahima; Tsymbalov, Sofya
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 144 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001072703	A1	20011004	WO 2001-US9433	20010323 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2402436	AA	20011004	CA 2001-2402436	20010323 <--
US 2002019563	A1	20020214	US 2001-816577	20010323

US 6403830	B2	20020611		
US 2002111493	A1	20020815	US 2001-816575	20010323
US 6586474	B2	20030701		
EP 1265860	A1	20021218	EP 2001-922636	20010323
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001009386	A	20030415	BR 2001-9386	20010323
ZA 2002006459	A	20030813	ZA 2002-6459	20010323
JP 2003528853	T2	20030930	JP 2001-570616	20010323
NZ 520812	A	20040430	NZ 2001-520812	20010323
ZA 2002006455	A	20030813	ZA 2002-6455	20020813
US 2003199701	A1	20031023	US 2002-321969	20021217
US 2004186178	A1	20040923	US 2004-815375	20040401
PRIORITY APPLN. INFO.:				
US 2000-191923P P 20000324				
US 2001-816575 A3 20010323				
WO 2001-US9433 W 20010323				
US 2002-321969 B3 20021217				

OTHER SOURCE(S): MARPAT 135:289056

AB The invention relates to S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-L-cysteine (1) or its pharmaceutically acceptable salts for use as nitric oxide synthase (NOS) inhibitors. Thus, 1.2HCl was prepared by a multistep procedure involving S-alkylation of (2R)-2-methyl-L-cysteine hydrochloride with Boc-NHCH₂CH₂Br (Boc = tert-butoxycarbonyl), deprotection, condensation with Et acetimidate hydrochloride, and acidolysis with 1 N HCl. (2R)-2-methyl-L-cysteine hydrochloride was obtained from (R)-cysteine Me ester hydrochloride. Inhibitory assays for compound 1.2HCl showed hINOS, hecNOS, hncNOS, and human cartilage IC₅₀ values 3.1, 77, 15 μM, and 0.7 μM, resp.


IT 148766-37-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amidino compds. useful as nitric oxide synthase inhibitors)

RN 148766-37-4 CAPLUS

CN L-Cysteine, 2-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:730697 CAPLUS

DOCUMENT NUMBER: 135:273215

TITLE: Preparation of amidino compounds useful as nitric oxide synthase inhibitors

INVENTOR(S): Webber, Ronald Keith; Awasthi, Alok K.; Bergmanis, Arija A.; Durley, Richard C.; Fok, Kam F.; Ganser, Scott S.; Hagen, Timothy J.; Hallinan, Ann E.; Hansen, Donald W.; Hickory, Brian S.; Manning, Pamela T.; Mao, Michael; Moermann, Alan E.; Pitzele, Barnett S.; Promo, Michelle A.; Schartman, Richard R.; Scholten, Jeffrey A.; Snyder, Jeffrey S.; Toth, Mihaly V.;


PATENT ASSIGNEE(S) : Trivedi, Mahima; Tsymbalov, Sofya; Tjoeng, Foe Siong
 Pharmacia Corporation, USA
 SOURCE: PCT Int. Appl., 159 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001072702	A2	20011004	WO 2001-US9431	20010323 <--
WO 2001072702	A3	20020919		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2402199	AA	20011004	CA 2001-2402199	20010323 <--
US 2002019563	A1	20020214	US 2001-816577	20010323
US 6403830	B2	20020611		
US 2002111493	A1	20020815	US 2001-816575	20010323
US 6586474	B2	20030701		
EP 1265859	A2	20021218	EP 2001-920718	20010323
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
ZA 2002006459	A	20030813	ZA 2002-6459	20010323
JP 2003528852	T2	20030930	JP 2001-570615	20010323
NZ 520813	A	20040528	NZ 2001-520813	20010323
ZA 2002006455	A	20030813	ZA 2002-6455	20020813
US 2003199701	A1	20031023	US 2002-321969	20021217
US 2004186178	A1	20040923	US 2004-815375	20040401
PRIORITY APPLN. INFO.:			US 2000-191923P	P 20000324
			US 2001-816575	A3 20010323
			WO 2001-US9431	W 20010323
			US 2002-321969	B3 20021217

OTHER SOURCE(S) : MARPAT 135:273215
 AB Amidino compds. R11N:CR13NR12CR9R10CR1R7-X-CR5R6CR2 (NR3R4) COR8 [X = S, SO,
 SO₂; R1, R5, R6, R7 = H, halo, alkyl (alkyl and other groups may be
 substituted), alkenyl, alkynyl, alkoxyalkyl; R2 = alkyl, alkenyl, alkynyl,
 alkoxyalkyl, alkylthioalkyl; R3 = H, OH, CHO, alkanoyl, CO₂H, C(O)SH or
 alkyl esters; R8 = OH, alkoxy, an amino or alkylamino group or R3 and R8
 may form a ring; R4 = H, CO₂H, carbalkoxy; R9, R10 = H, alkyl, alkenyl,
 alkynyl, alkoxyalkyl; R11, R12 = H, OH, CO₂H, C(O)SH or esters or R11 and
 R12 may form a ring; R13 = alkyl (with provisos)] or their salts were
 prepared as nitric oxide synthase (NOS) inhibitors. Thus,
 S-[2-[(1-iminoethyl)aminooethyl]-2-methyl-L-cysteine dihydrochloride (1)
 was prepared by a multistep procedure involving S-alkylation of
 (2R)-2-methyl-L-cysteine hydrochloride with Boc-NHCH₂CH₂Br (Boc =
 tert-butoxycarbonyl), deprotection, condensation with Et acetimidate
 hydrochloride, and acidolysis with 1 N HCl. (2R)-2-methyl-L-cysteine
 hydrochloride was obtained from (R)-cysteine Me ester hydrochloride.
 Inhibitory assays for compound 1 showed hiNOS, hecNOS, hncNOS, and human
 cartilage IC₅₀ values 3.1, 77, 15 μM, and 0.7 μM, resp.


IT 148766-37-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of amidino compds. useful as nitric oxide synthase inhibitors)
 RN 148766-37-4 CAPLUS
 CN L-Cysteine, 2-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1995:657309 CAPLUS
 DOCUMENT NUMBER: 123:83804
 TITLE: Total synthesis of thiangazole, a novel naturally occurring HIV-1 inhibitor from Polyangium sp
 AUTHOR(S): Boyce, Richard J.; Mulqueen, Gerard C.; Pattenden, Gerald
 CORPORATE SOURCE: Dep. Chemistry, Nottingham Univ., Nottingham, NG7 2RD, UK
 SOURCE: Tetrahedron (1995), 51(26), 7321-30
 CODEN: TETRAB; ISSN: 0040-4020
 PUBLISHER: Pergamon
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 123:83804
 GI



AB The total synthesis of the cinnamyl-oxazole substituted tris-thiazoline containing metabolite (-)-thiangazole is described. The synthesis is based on elaboration of the R-2-methylcysteine derived bis-thiazoline nitrile I and oxazole II intermediates, followed by a cyclocondensation reaction between I and II, and treatment of the resulting tris-thiazoline oxazole ester with methylamine.


IT 148766-37-4

RL: RCT (Reactant); RACT (Reactant or reagent)
 (total synthesis of thiangazole)

RN 148766-37-4 CAPLUS


CN L-Cysteine, 2-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1994:8366 CAPLUS
 DOCUMENT NUMBER: 120:8366
 TITLE: Synthesis of the thiazoline-based siderophore
 (S)-desferrithiocin
 AUTHOR(S): Mulqueen, Gerard C.; Pattenden, Gerald; Whiting,
 Donald A.
 CORPORATE SOURCE: Dep. Chem., Univ. Nottingham, Nottingham, NG7 2RD, UK
 SOURCE: Tetrahedron (1993), 49(24), 5359-64
 DOCUMENT TYPE: CODEN: TETRAB; ISSN: 0040-4020
 LANGUAGE: Journal
 GI English



AB A total synthesis of (S)-desferrithiocin (I), isolated from *Streptomyces antibioticus*, is described. Thus, a concise synthesis of (S)-2-methylcysteine hydrochloride is first developed based on a modification of Seebach's self-reproduction of chirality protocol using the thiazolidine intermediate II derived from (S)-cysteine and pivalaldehyde as a key intermediate. When a solution of (S)-2-methylcysteine hydrochloride is heated with 2-cyano-3-hydroxypyridine in the presence of triethylamine, I is produced in 97% yield. In a similar manner, use of (R)-2-methylcysteine in a cyclocondensation with 2-cyano-3-hydroxypyridine led to (R)-desferrithiocin, in a similar yield.


IT 148766-37-4

RL: RCT (Reactant); RACT (Reactant or reagent)
 (intermediate in desferrithiocin total synthesis)

RN 148766-37-4 CAPLUS


CN L-Cysteine, 2-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1993:473043 CAPLUS
 DOCUMENT NUMBER: 119:73043
 TITLE: Enantioselective synthesis of 2-alkyl substituted cysteines
 AUTHOR(S): Pattenden, Gerald; Thom, Stephen M.; Jones, Martin F.
 CORPORATE SOURCE: Dep. Chem., Univ. Nottingham, Nottingham, NG7 2RD, UK
 SOURCE: Tetrahedron (1993), 49(10), 2131-8
 CODEN: TETRAB; ISSN: 0040-4020
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 119:73043
 GI



AB Treatment of (R)-cysteine-derived thiazolidine derivative I with LDA-DMPU at -90°, followed by alkylation with MeI gave methylated thiazolidine II containing the Me and tert-Bu groups virtually exclusively anti to one another. Hydrolysis of II by 5M HCl gave (R)-2-methylcysteine hydrochloride (III) in excellent yield and enantiomeric purity. A range of other 2-alkyl substituted cysteines of excellent optical purity are prepared by this modification of Seebach's "self-reproduction of chirality" protocol.


IT 148766-37-4P

RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
 (enantioselective synthesis of)

RN 148766-37-4 CAPLUS

CN L-Cysteine, 2-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

=> d his

(FILE 'HOME' ENTERED AT 14:46:08 ON 22 FEB 2005)

FILE 'CAPLUS' ENTERED AT 14:46:26 ON 22 FEB 2005
L1 STRUCTURE UPLOADED
S L1

FILE 'REGISTRY' ENTERED AT 14:47:01 ON 22 FEB 2005
L2 2 S L1

FILE 'CAPLUS' ENTERED AT 14:47:01 ON 22 FEB 2005
L3 18 S L2
L4 5 S L3 AND PY<2002

=> s 11 full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 14:50:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3203 TO ITERATE

100.0% PROCESSED 3203 ITERATIONS
SEARCH TIME: 00.00.01

20 ANSWERS

L5 20 SEA SSS FUL L1

L6 55 L5

=> s 16 and py<2002
21606142 PY<2002
L7 32 L6 AND PY<2002

=> s 17 and (alkyl or cycloalkyl)
544455 ALKYL
42316 CYCLOALKYL
L8 6 L7 AND (ALKYL OR CYCLOALKYL)

=> d 1-6 ibib abs hitstr

L8 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:730697 CAPLUS
DOCUMENT NUMBER: 135:273215
TITLE: Preparation of amidino compounds useful as nitric oxide synthase inhibitors
INVENTOR(S): Webber, Ronald Keith; Awasthi, Alok K.; Bergmanis, Arija A.; Durley, Richard C.; Fok, Kam F.; Ganser, Scott S.; Hagen, Timothy J.; Hallinan, Ann E.; Hansen, Donald W.; Hickory, Brian S.; Manning, Pamela T.; Mao, Michael; Moormann, Alan E.; Pitzele, Barnett S.; Prom, Michelle A.; Schartman, Richard R.; Scholten, Jeffrey A.; Snyder, Jeffrey S.; Toth, Mihaly V.; Trivedi, Mahima; Tsymbalov, Sofya; Tjoeng, Foe Siong
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 159 pp.

CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001072702	A2	20011004	WO 2001-US9431	20010323 <--
WO 2001072702	A3	20020919		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2402199	AA	20011004	CA 2001-2402199	20010323 <--
US 2002019563	A1	20020214	US 2001-816577	20010323
US 6403830	B2	20020611		
US 2002111493	A1	20020815	US 2001-816575	20010323
US 6586474	B2	20030701		
EP 1265859	A2	20021218	EP 2001-920718	20010323
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2002006459	A	20030813	ZA 2002-6459	20010323
JP 2003528852	T2	20030930	JP 2001-570615	20010323
NZ 520813	A	20040528	NZ 2001-520813	20010323
ZA 2002006455	A	20030813	ZA 2002-6455	20020813
US 2003199701	A1	20031023	US 2002-321969	20021217
US 2004186178	A1	20040923	US 2004-815375	20040401
PRIORITY APPLN. INFO.:			US 2000-191923P	P 20000324
			US 2001-816575	A3 20010323
			WO 2001-US9431	W 20010323
			US 2002-321969	B3 20021217


OTHER SOURCE(S): MARPAT 135:273215

AB Amidino compds. R11N:CR13NR12CR9R10CR1R7-X-CR5R6CR2 (NR3R4) COR8 [X = S, SO, SO₂; R1, R5, R6, R7 = H, halo, alkyl (alkyl and other groups may be substituted), alkenyl, alkynyl, alkoxyalkyl; R2 = alkyl, alkenyl, alkynyl, alkoxyalkyl, alkylthioalkyl; R3 = H, OH, CHO, alkanoyl, CO₂H, C(O)SH or alkyl esters; R8 = OH, alkoxy, an amino or alkylamino group or R3 and R8 may form a ring; R4 = H, CO₂H, carbalkoxy; R9, R10 = H, alkyl, alkenyl, alkynyl, alkoxyalkyl; R11, R12 = H, OH, CO₂H, C(O)SH or esters or R11 and R12 may form a ring; R13 = alkyl (with provisos)] or their salts were prepared as nitric oxide synthase (NOS) inhibitors. Thus, S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-L-cysteine dihydrochloride (1) was prepared by a multistep procedure involving S-alkylation of (2R)-2-methyl-L-cysteine hydrochloride with Boc-NHCH₂CH₂Br (Boc = tert-butoxycarbonyl), deprotection, condensation with Et acetimidate hydrochloride, and acidolysis with 1 N HCl. (2R)-2-methyl-L-cysteine hydrochloride was obtained from (R)-cysteine Me ester hydrochloride. Inhibitory assays for compound 1 showed hNOS, hecNOS, hncNOS, and human cartilage IC₅₀ values 3.1, 77, 15 μM, and 0.7 μM, resp.

IT 148766-37-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of amidino compds. useful as nitric oxide synthase inhibitors)

RN 148766-37-4 CAPLUS
 CN L-Cysteine, 2-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L8 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1998:163575 CAPLUS
 DOCUMENT NUMBER: 128:204913
 TITLE: Preparation of thiazepinecarboxamide derivatives and related heterocycles as metalloprotease inhibitors
 INVENTOR(S): De, Biswanath; Natchus, Michael George; Pikul, Stanislaw; Almstead, Neil Gregory; Matthews, Randall Stryker; Taiwo, Yetunde Olabisi; Cheng, Menyan
 PATENT ASSIGNEE(S): Procter & Gamble Company, USA
 SOURCE: PCT Int. Appl., 62 pp.
 CODEN: PIIXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9808827	A1	19980305	WO 1997-US14551	19970822 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2264045	AA	19980305	CA 1997-2264045	19970822 <--
AU 9741529	A1	19980319	AU 1997-41529	19970822 <--
AU 731319	B2	20010329		
EP 925287	A1	19990630	EP 1997-939442	19970822 <--
EP 925287	B1	20030115		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1228773	A	19990915	CN 1997-197541	19970822 <--
CN 1232457	A	19991020	CN 1997-198547	19970822 <--
BR 9713185	A	19991103	BR 1997-13185	19970822 <--
JP 2000515166	T2	20001114	JP 1998-511711	19970822 <--
NZ 334252	A	20001124	NZ 1997-334252	19970822 <--
AT 231132	E	20030215	AT 1997-939442	19970822
US 6166005	A	20001226	US 1997-921953	19970826 <--
ZA 9707694	A	19980223	ZA 1997-7694	19970827 <--
ZA 9707695	A	19980223	ZA 1997-7695	19970827 <--
NO 9900839	A	19990428	NO 1999-839	19990222 <--
KR 2000035917	A	20000626	KR 1999-701653	19990227 <--
KR 2000035923	A	20000626	KR 1999-701659	19990227 <--
US 6545038	B1	20030408	US 2000-707212	20001106
US 2003186958	A1	20031002	US 2003-361115	20030206
PRIORITY APPLN. INFO.:			US 1996-24764P	P 19960828
			WO 1997-US14551	W 19970822
			US 1997-921953	A3 19970826

OTHER SOURCE(S) :
GI

MARPAT 128:204913

US 2000-707212

A3 20001106




AB I [R1 = H; R2 = H, alkyl, acyl; Ar = COR3, SO2R4; R3 = alkoxy, alkyl, aryl, etc.; R4 = alkyl, heteroalkyl, aryl, heteroaryl; X = CH2, O, S, SO, SO2, NR5; R5 = H, alkyl, etc.; W = H, alkylene or arylene or heteroarylene bridge between two carbons; Y = H, OH, amino, etc.; Z = -, H, spiro moiety, oxo; n = 1-3], inhibitors of metalloproteases (no data), were prepared. E.g., N-hydroxy-2,2-dimethyl-S,S-dioxo-4-[(4-methoxyphenyl)sulfonyl]thiazepine-3(S)-carboxamide was prepared using D-penicillamine and 4-methoxybenzenesulfonyl chloride as starting materials.

IT 151062-55-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazepinecarboxamide derivs. and related heterocycles as metalloprotease inhibitors)

RN 151062-55-4 CAPLUS

CN D-Cysteine, 2-methyl-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1993:473043 CAPLUS
DOCUMENT NUMBER: 119:73043
TITLE: Enantioselective synthesis of 2-alkyl substituted cysteines
AUTHOR(S): Pattenden, Gerald; Thom, Stephen M.; Jones, Martin F.
CORPORATE SOURCE: Dep. Chem., Univ. Nottingham, Nottingham, NG7 2RD, UK
SOURCE: Tetrahedron (1993), 49(10), 2131-8
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S) : CASREACT 119:73043
GI



AB Treatment of (R)-cysteine-derived thiazolidine derivative I with LDA-DMPU at -90°, followed by alkylation with MeI gave methylated thiazolidine II containing the Me and tert-Bu groups virtually exclusively anti to one another. Hydrolysis of II by 5M HCl gave (R)-2-methylcysteine hydrochloride (III) in excellent yield and enantiomeric purity. A range of other 2-alkyl substituted cysteines of excellent optical purity are prepared by this modification of Seebach's "self-reproduction of chirality" protocol.


IT 148766-37-4P

RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(enantioselective synthesis of)

RN 148766-37-4 CAPLUS

CN L-Cysteine, 2-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


IT 120519-93-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 120519-93-9 CAPLUS

CN L-Cysteine, 2-methyl-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L8 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1989:231195 CAPLUS

DOCUMENT NUMBER: 110:231195

TITLE: Asymmetric catalysis. XL. Enantioselective hydrosilylation of ketones by diphenylsilane with 1,5-cyclooctadienierhodium chloride dimer-pyridinethiazolidine catalysts


AUTHOR(S): Brunner, Henri; Kuerzinger, Alfred
 CORPORATE SOURCE: Inst. Anorg. Chem., Univ. Regensburg, Regensburg,
 D-8400, Fed. Rep. Ger.
 SOURCE: Journal of Organometallic Chemistry (1988),
 346(3), 413-24
 CODEN: JORCAI; ISSN: 0022-328X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 110:231195

AB Fifty-eight prochiral ketones have been used in enantioselective hydrosilylation with Ph₂SiH₂ promoted by in-situ catalysts consisting of [Rh(COD)Cl]₂ (COD = 1,5-cyclooctadiene) and the chiral ligands (4S)-2-methyl-2-(2-pyridyl)-4-carbomethoxy-1,3-thiazolidine (I) and (4S)-2-(2-pyridyl)-4-carbethoxy-1,3-thiazolidine (II). Hydrolysis of the silyl ethers gave the corresponding secondary alcs. Aryl Me ketones were reduced with enantiomeric excesses (ee's) better than 80% irresp. of whether the substituents Me, Cl, F, OMe were in o-, m-, or p- position of the Ph ring. The only exceptions were ketones containing the p-OMe substituent, for which a p-methoxy effect diminished the optical yields. Heterocyclic ketones were also hydrosilylated with high optical inductions, e.g. 2-acetylpyridine with 88.5% ee. Linear **alkyl** ketones with the CO group in the 2-position (Me ketones) gave up to 50% ee R, in contrast to the corresponding Et ketones with the CO group in 3-position, which gave predominantly S configurated products. In 35 cases the asym. inductions were higher with ligand II than with ligand I.

IT 120519-93-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (cyclocondensation of, with acetylpyridine)

RN 120519-93-9 CAPLUS
CN L-Cysteine, 2-methyl-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

IT 120519-94-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (cyclocondensation of, with pyridinecarboxaldehyde)


RN 120519-94-0 CAPLUS
CN L-Cysteine, 2-methyl-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


L8 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1987:435786 CAPLUS
 DOCUMENT NUMBER: 107:35786
 TITLE: Radioprotective and radiosensitizing effects of sulfur-containing amino acid derivatives on *E. coli* and mice
 AUTHOR(S): Nishimura, Akihisa
 CORPORATE SOURCE: Radiol. Technol. Course, Kurashiki Paramed. Coll., Kurashiki, 701-01, Japan
 SOURCE: Okayama Igakkai Zasshi (1986), 98(9/10), 827-50
 CODEN: OIZAAV; ISSN: 0030-1558
 DOCUMENT TYPE: Journal
 LANGUAGE: Japanese
 AB Both protection and sensitization of *Escherichia coli* and C57BL mice against 60Co γ -rays with S-containing amino acid derivs. (S-alkyl-L-cysteines, S-alkyl-2-methyl-DL-cysteines and their hydration derivs. and sulfoxides of these compds.) were examined. *E. coli* Cells (10⁶/mL) in 20 mM aqueous solution of the S compds. was irradiated with 60 Gy of γ -rays. Mice (5-wk-old males) were subjected to 7.5 Gy of γ -rays after a single i.p. injection of 0.75 mmol/kg body weight of each compound. In the case of *E. coli*, S-alkyl compds. were more effective than S-Pr ones for protection, and sulfoxide amino acids exhibited a radiosensitization effect. The replacement of the α -H of S-substituted cysteines by Me groups decreased the radioprotective effect. The hydantoin derivs. such as DL-5-allylthiomethylhydantoin were much more radioprotective than the original amino acids. In mice, DL-5-allylthio-methyl-5-methylhydantoin and DL-5-propylthiomethylhydantoin (0.75 mmole/kg) had a marked radioprotective effect. The survival ratios were 6.33 and 6.67, or the dose reduction factors (DRF) were 1.41 and 1.53, resp. On the other hand, DL-5-allylthiomethyl-5-methylhydantoin sulfoxide had a radiosensitizing effect, with a survival ratio of 0.333 and a DRF of 0.517.
 IT 22681-73-8D, S-alkyl derivs.
 RL: BIOL (Biological study)
 (gamma ray effect on *Escherichia coli* and mice modification by)
 RN 22681-73-8 CAPLUS
 CN Cysteine, 2-methyl- (8CI, 9CI) (CA INDEX NAME)



L8 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1956:91190 CAPLUS
 DOCUMENT NUMBER: 50:91190
 ORIGINAL REFERENCE NO.: 50:17149a-c
 TITLE: Biological protection against radiation. XIV. Further researches on the specificity of radiation protection action of cysteine-cysteamine and various sulphhydryl compounds
 AUTHOR(S): Langendorff, Hanns; Koch, Ruprecht
 SOURCE: Strahlentherapie (1956), 99, 567-76
 CODEN: STRAAA; ISSN: 0039-2073
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 AB cf. C.A. 50, 9456i. Expts. are described on the protection against x-rays carried out in rats and mice. Examined were N-alkyl-substituted

cysteamines and cystamines, N-phenyl-substituted cysteamines, acid amides of cysteamine, isocysteine, β -homocysteine, α -methylcysteine, N-diethylhomocysteamine, as well as mercapto(amino)heptane and mercapto(amino)pentane. The results of these expts. confirm that the protective effect of the sulphydryl bodies is bound to the base constitution $HS(CH_2)_xNRR'$, in which x must probably not be higher than 3 and R and R' have to be alkyl-substituting compds. The α -thio amino acids, which correspond to the base constitution, are efficacious, as well, whereas the β -isomeric compds. evidently produce an effect of sensitization.


IT 22681-73-8, Cysteine, 2-methyl-
(radioprotective activity of)
RN 22681-73-8 CAPLUS
CN Cysteine, 2-methyl- (8CI, 9CI) (CA INDEX NAME)



```
=>  
Uploading C:\STNEXP4\QUERIES\824a.str
```

```
L9      STRUCTURE UPLOADED
```

```
=> d 19  
L9 HAS NO ANSWERS  
L9      STR
```



```
Structure attributes must be viewed using STN Express query preparation.
```

```
=> s 19  
REGISTRY INITIATED  
Substance data SEARCH and crossover from CAS REGISTRY in progress...  
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.
```

```
SAMPLE SEARCH INITIATED 14:58:49 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 85 TO ITERATE
```

```
100.0% PROCESSED      85 ITERATIONS          9 ANSWERS  
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**  
                        BATCH   **COMPLETE**  
PROJECTED ITERATIONS:    1147 TO     2253  
PROJECTED ANSWERS:       9 TO      360
```

```
L10      9 SEA SSS SAM L9
```

```
L11      10 L10
```

```
=> s 19 full  
REGISTRY INITIATED  
Substance data SEARCH and crossover from CAS REGISTRY in progress...  
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.
```

```
FULL SEARCH INITIATED 14:58:59 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1455 TO ITERATE
```

100.0% PROCESSED 1455 ITERATIONS
SEARCH TIME: 00.00.01

164 ANSWERS

L12 164 SEA SSS FUL L9

L13 16 L12

=> s l13 and py<2002
21606142 PY<2002
L14 2 L13 AND PY<2002

=> d 1-2 ibib abs hitstr

L14 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:730698 CAPLUS
DOCUMENT NUMBER: 135:289056
TITLE: Preparation of amidino compounds useful as nitric oxide synthase inhibitors
INVENTOR(S): Webber, Ronald Keith; Awasthi, Alok K.; Bergmanis, Arija A.; Durley, Richard C.; Ganser, Scott S.; Hagen, Timothy J.; Hallinan, Ann E.; Hansen, Donald W.; Hickory, Brian S.; Moermann, Alan E.; Pitzele, Barnett S.; Promo, Michelle A.; Schartman, Richard R.; Snyder, Jeffrey S.; Trivedi, Mahima; Tsymbalov, Sofya
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 144 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001072703	A1	20011004	WO 2001-US9433	20010323 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2402436	AA	20011004	CA 2001-2402436	20010323 <--
US 2002019563	A1	20020214	US 2001-816577	20010323
US 6403830	B2	20020611		
US 2002111493	A1	20020815	US 2001-816575	20010323
US 6586474	B2	20030701		
EP 1265860	A1	20021218	EP 2001-922636	20010323
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001009386	A	20030415	BR 2001-9386	20010323
ZA 2002006459	A	20030813	ZA 2002-6459	20010323
JP 2003528853	T2	20030930	JP 2001-570616	20010323
NZ 520812	A	20040430	NZ 2001-520812	20010323
ZA 2002006455	A	20030813	ZA 2002-6455	20020813
US 2003199701	A1	20031023	US 2002-321969	20021217
US 2004186178	A1	20040923	US 2004-815375	20040401
PRIORITY APPLN. INFO.:			US 2000-191923P	P 20000324
			US 2001-816575	A3 20010323
			WO 2001-US9433	W 20010323

OTHER SOURCE(S): MARPAT 135:289056

AB The invention relates to S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-L-cysteine (1) or its pharmaceutically acceptable salts for use as nitric oxide synthase (NOS) inhibitors. Thus, 1.2HCl was prepared by a multistep procedure involving S-alkylation of (2R)-2-methyl-L-cysteine hydrochloride with Boc-NHCH₂CH₂Br (Boc = tert-butoxycarbonyl), deprotection, condensation with Et acetimidate hydrochloride, and acidolysis with 1 N HCl. (2R)-2-methyl-L-cysteine hydrochloride was obtained from (R)-cysteine Me ester hydrochloride. Inhibitory assays for compound 1.2HCl showed hINOS, hecNOS, hncNOS, and human cartilage IC₅₀ values 3.1, 77, 15 μM, and 0.7 μM, resp.

IT 364067-16-3P 364067-34-5P 364067-35-6P

364067-36-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of amidino compds. useful as nitric oxide synthase inhibitors)

RN 364067-16-3 CAPLUS

CN L-Cysteine, S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

L14 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2001:730697 CAPLUS
 DOCUMENT NUMBER: 135:273215
 TITLE: Preparation of amidino compounds useful as nitric oxide synthase inhibitors
 INVENTOR(S): Webber, Ronald Keith; Awasthi, Alok K.; Bergmanis, Arija A.; Durley, Richard C.; Fok, Kam F.; Ganser, Scott S.; Hagen, Timothy J.; Hallinan, Ann E.; Hansen, Donald W.; Hickory, Brian S.; Manning, Pamela T.; Mao, Michael; Moormann, Alan E.; Pitzele, Barnett S.; Promio, Michelle A.; Schartman, Richard R.; Scholten, Jeffrey A.; Snyder, Jeffrey S.; Toth, Mihaly V.; Trivedi, Mahima; Tsymbalov, Sofya; Tjoeng, Foe Siong
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA
 SOURCE: PCT Int. Appl., 159 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001072702	A2	20011004	WO 2001-US9431	20010323 <--
WO 2001072702	A3	20020919		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2402199	AA	20011004	CA 2001-2402199	20010323 <--
US 2002019563	A1	20020214	US 2001-816577	20010323
US 6403830	B2	20020611		
US 2002111493	A1	20020815	US 2001-816575	20010323
US 6586474	B2	20030701		
EP 1265859	A2	20021218	EP 2001-920718	20010323
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2002006459	A	20030813	ZA 2002-6459	20010323
JP 2003528852	T2	20030930	JP 2001-570615	20010323
NZ 520813	A	20040528	NZ 2001-520813	20010323
ZA 2002006455	A	20030813	ZA 2002-6455	20020813
US 2003199701	A1	20031023	US 2002-321969	20021217
US 2004186178	A1	20040923	US 2004-815375	20040401
PRIORITY APPLN. INFO.:			US 2000-191923P	P 20000324
			US 2001-816575	A3 20010323
			WO 2001-US9431	W 20010323
			US 2002-321969	B3 20021217

OTHER SOURCE(S): MARPAT 135:273215
 AB Amidino compds. R11N:CR13NR12CR9R10CR1R7-X-CR5R6CR2(NR3R4)COR8 [X = S, SO, SO₂; R1, R5, R6, R7 = H, halo, alkyl (alkyl and other groups may be substituted), alkenyl, alkynyl, alkoxyalkyl; R2 = alkyl, alkenyl, alkynyl, alkoxyalkyl, alkylthioalkyl; R3 = H, OH, CHO, alkanoyl, CO₂H, C(O)SH or alkyl esters; R8 = OH, alkoxy, an amino or alkylamino group or R3 and R8 may form a ring; R4 = H, CO₂H, carbalkoxy; R9, R10 = H, alkyl, alkenyl, alkynyl, alkoxyalkyl; R11, R12 = H, OH, CO₂H, C(O)SH or esters or R11 and R12 may form a ring; R13 = alkyl (with provisos)] or their salts were prepared as nitric oxide synthase (NOS) inhibitors. Thus, S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-L-cysteine dihydrochloride (1)

was prepared by a multistep procedure involving S-alkylation of (2R)-2-methyl-L-cysteine hydrochloride with Boc-NHCH₂CH₂Br (Boc = tert-butoxycarbonyl), deprotection, condensation with Et acetimidate hydrochloride, and acidolysis with 1 N HCl. (2R)-2-methyl-L-cysteine hydrochloride was obtained from (R)-cysteine Me ester hydrochloride. Inhibitory assays for compound 1 showed hiNOS, hecNOS, hncNOS, and human cartilage IC₅₀ values 3.1, 77, 15 μM, and 0.7 μM, resp.

IT 364067-16-3P 364067-34-5P 364067-35-6P


364067-36-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of amidino compds. useful as nitric oxide synthase inhibitors)

RN 364067-16-3 CAPLUS

CN L-Cysteine, S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 364067-34-5 CAPLUS

CN D-Cysteine, S-(2-aminoethyl)-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 364067-35-6 CAPLUS

CN D-Cysteine, S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 364067-36-7 CAPLUS


CN L-Cysteine, S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-, monoacetate (9CI)
(CA INDEX NAME)

CM 1

CRN 364067-22-1

CMF C8 H17 N3 O2 S


Absolute stereochemistry.



CM 2

CRN 64-19-7

CMF C2 H4 O2



IT 364067-22-1DP, IPR (amberlite)-69 salt 364067-22-1P
 364067-23-2P 364067-24-3P 364067-25-4P
 364067-26-5P 364067-27-6P 364067-28-7P
 364067-38-9P 364067-39-0P 364067-40-3P
 364067-41-4P 364067-42-5P 364067-43-6P
 364067-44-7P 364067-45-8P 364067-46-9P
 364067-47-0P 364067-48-1P 364067-49-2P
 364067-50-5P 364067-51-6P 364067-52-7P
 364067-53-8P 364067-54-9P 364067-55-0P
 364067-56-1P 364067-57-2P 364067-58-3P
 364067-59-4P 364067-60-7P 364067-61-8P
 364067-62-9P 364067-64-1P 364067-65-2P
 364067-66-3P 364067-67-4P 364067-68-5P
 364067-69-6P 364067-70-9P 364067-71-0P
 364067-72-1P 364067-73-2P 364067-74-3P
 364067-75-4P 364067-76-5P 364067-77-6P
 364067-78-7P 364067-79-8P 364067-80-1P
 364067-81-2P 364067-82-3P 364067-83-4P
 364067-84-5P 364067-85-6P 364067-86-7P
 364067-87-8P 364067-88-9P 364067-89-0P
 364067-90-3P 364067-91-4P 364067-92-5P
 364067-93-6P 364067-94-7P 364067-95-8P
 364067-96-9P 364067-97-0P 364067-98-1P

364067-99-2P 364068-00-8P 364068-01-9P
364068-02-0P 364068-03-1P 364068-04-2P
364068-05-3P 364068-06-4P 364068-07-5P
364068-08-6P 364068-09-7P 364068-10-0P
364068-11-1P 364068-12-2P 364068-13-3P
364068-14-4P 364068-15-5P 364068-51-9P
364068-52-0P 364068-53-1P 364068-54-2P
364068-55-3P 364068-56-4P 364068-57-5P
364068-58-6P 364068-59-7P 364068-60-0P
364068-61-1P 364068-62-2P 364068-63-3P
364068-64-4P 364068-65-5P 364068-66-6P
364068-67-7P 364068-68-8P 364068-69-9P
364068-70-2P 364068-71-3P 364068-73-5P
364068-74-6P 364068-75-7P 364068-77-9P
364068-78-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amidino compds. useful as nitric oxide synthase inhibitors)

RN 364067-22-1 CAPLUS

CN L-Cysteine, S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl- (9CI) (CA INDEX NAME)